Page 1086 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 60 Myelodysplastic Syndromes 969

Greenberg PL, Tuechler H, Schanz J, et al: Revised international prognostic Papaemmanuil E, Gerstung M, Malcovati L, et al: Clinical and biological
scoring system for myelodysplastic syndromes. Blood 120(12):2454–2465, implications of driver mutations in myelodysplastic syndromes. Blood
2012. 122(22):3616–3627, quiz 3699, 2013.
Haferlach T, Nagata Y, Grossmann V, et al: Landscape of genetic lesions in Pascal L, Beyne-Rauzy O, Brechignac S, et al: Cardiac iron overload
944 patients with myelodysplastic syndromes. Leukemia 28(2):241–247, assessed by T2* magnetic resonance imaging and cardiac function in
2014. regularly transfused myelodysplastic syndrome patients. Br J Haematol
Hahn CN, Chong C-E, Carmichael CL, et al: Heritable GATA2 mutations 162(3):413–415, 2013.
associated with familial myelodysplastic syndrome and acute myeloid Saunthararajah Y, Sekeres M, Advani A, et al: Evaluation of noncytotoxic
leukemia. Nat Genet 43(10):1012–1017, 2011. DNMT1-depleting therapy in patients with myelodysplastic syndromes.
Hahn T, McCarthy PL, Hassebroek A, et al: Significant improvement in J Clin Invest 2015.
survival after allogeneic hematopoietic cell transplantation during a period Schanz J, Tüchler H, Solé F, et al: New comprehensive cytogenetic scoring
of significantly increased use, older recipient age, and use of unrelated system for primary myelodysplastic syndromes (MDS) and oligoblastic
donors. J Clin Oncol 31(19):2437–2449, 2013. acute myeloid leukemia after MDS derived from an international database
Jaiswal S, Fontanillas P, Flannick J, et al: Age-related clonal hematopoiesis merge. J Clin Oncol 30(8):820–829, 2012.
associated with adverse outcomes. N Engl J Med 371(26):2488–2498, Schneider RK, Ademà V, Heckl D, et al: Role of casein kinase 1A1 in the
2014. biology and targeted therapy of del(5q) MDS. Cancer Cell 26(4):509–520,
Kon A, Shih L-Y, Minamino M, et al: Recurrent mutations in multiple 2014.
components of the cohesin complex in myeloid neoplasms. Nat Genet Steensma DP: Dysplasia has A differential diagnosis: distinguishing genuine
45(10):1232–1237, 2013. myelodysplastic syndromes (MDS) from mimics, imitators, copycats and
Kuter DJ, Begley CG: Recombinant human thrombopoietin: basic biology impostors. Curr Hematol Malig Rep 7(4):310–320, 2012.
and evaluation of clinical studies. Blood 100(10):3457–3469, 2002. Steensma DP: Historical perspectives on myelodysplastic syndromes. Leuk
List A, Kurtin S, Roe DJ, et al: Efficacy of lenalidomide in myelodysplastic Res 36:1441, 2012.
syndromes. N Engl J Med 352(6):549–557, 2005. Walter MJ, Shen D, Ding L, et al: Clonal architecture of secondary acute
Lyons RM, Marek BJ, Paley C, et al: Comparison of 24-month outcomes myeloid leukemia. N Engl J Med 366(12):1090–1098, 2012.
in chelated and non-chelated lower-risk patients with myelodysplas- Yoshida K, Sanada M, Shiraishi Y, et al: Frequent pathway mutations of
tic syndromes in a prospective registry. Leuk Res 38(2):149–154, splicing machinery in myelodysplasia. Nature 478(7367):64–69, 2011.
2014. Yoshizato T, Dumitriu B, Hosokawa K, et al: Somatic mutations and clonal
Nikoloski G, Langemeijer SMC, Kuiper RP, et al: Somatic mutations of the hematopoiesis in aplastic anemia. N Engl J Med 373(1):35–47, 2015.
histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat
Genet 42(8):665–667, 2010.
Papaemmanuil E, Cazzola M, Boultwood J, et al: Somatic SF3B1 mutation in REFERENCES
myelodysplasia with ring sideroblasts. N Engl J Med 365(15):1384–1395,
2011. For the complete list of references, log on to www.expertconsult.com.